-+ 0.00%
-+ 0.00%
-+ 0.00%

Vaxcyte Hits Enrollment Cap For Phase 3 Trials For VAX-31, A Pneumococcal Conjugate Vaccine Candidate

Benzinga·03/23/2026 12:35:33
Listen to the news

Vaxcyte's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults was finalized in consultation and alignment with the U.S. Food and Drug Administration (FDA) and is intended to generate a broad and robust dataset to support a planned Biologics License Application (BLA) submission.